The 2.61-year claim is the central marketing finding of the Aging Cell trial and the primary public-facing result deployed by Circulate Health in its commercial materials. The figure is internally consistent with the trial methodology and statistical analysis (FDR=6.22e-05 across the 35-clock panel, single-blind randomized placebo-controlled design, N=42). Verification status is currently unreplicated: no independent replication by groups unaffiliated with Circulate has been published, and the endpoint itself (epigenetic age across a multi-clock panel) is a surrogate not validated as a causal mediator of mortality at the individual level. The claim is internally rigorous within the framework of the single trial that produced it; the gap is between the trial result and the broader clinical claim being made on its basis.